SCHEMBL5017869

SCHEMBL5017869

CC(F)(C(=O)O)C(=O)NCc1cc(F)cc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.41
MMP8 P22894 1/20 0.40
METAP2 P50579 3/20 0.40
HPGD P15428 1/20 0.40
HDAC6 Q9UBN7 1/20 0.39
PDE10A Q9Y233 1/20 0.38
AURKA O14965 1/20 0.37
CYP3A4 P08684 2/20 0.37
ALDH1A1 P00352 1/20 0.37
EGLN1 Q9GZT9 1/20 0.36
CNR2 P34972 1/20 0.36
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
SMO Q99835 1/20 0.36
HTT P42858 1/20 0.36
OPRK1 P41145 1/20 0.35
CCNE2 O96020 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1562580 0.85 RIPK1 (0.41) RIPK1MMP8METAP2HPGDHDAC6
SCHEMBL1561651 0.79 PDE10A (0.37) RIPK1METAP2HPGDPDE10AAURKA
SCHEMBL3563691 0.75 METAP2 (0.47) RIPK1METAP2AURKAALDH1A1EGLN1
SCHEMBL18630728 0.74 NPC1 (0.55) HPGDHDAC6ALDH1A1
SCHEMBL28760659 0.74 NPC1 (0.55) HPGDHDAC6ALDH1A1
SCHEMBL885252 0.73 KMT2A (0.48) RIPK1METAP2HDAC6PDE10AAURKA
SCHEMBL18415454 0.73 METAP2 (0.49) RIPK1METAP2PDE10AAURKAALDH1A1
SCHEMBL5022433 0.73 CYP3A4 (0.43) CYP3A4ALDH1A1CNR2OPRK1
SCHEMBL5022438 0.73 CYP3A4 (0.43) CYP3A4ALDH1A1CNR2OPRK1
SCHEMBL12791343 0.72 GRM2 (0.46) METAP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592684-B1 MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS HOFFMANN LA ROCHE (CH) 2008-07-30 EP disclosed
US-7375099-B2 secretase inhibitors; therapy for Alzheimer's disease HOFFMANN-LA ROCHE INC. (US) 2008-05-20 US disclosed
EP-1592684-A1 MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-09 EP disclosed
US-20040220222-A1 Malonamide derivatives F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-11-04 US disclosed
WO-2004069826-A1 MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220222-A1 Malonamide derivatives BACE1, BACE2, APP RIPK1 1978/4885MMP8 4774/4885METAP2 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.